TrialsgrambetaRCTs are beautiful

Acute kidney injury

Renal-replacement timing and dose, contrast-associated AKI and care bundles.

Trials
9
Years
2008–2021
Sort
  • 2021AKIKI 2⁠RRT timingIn 278 patients with AKI and no urgent indication, a more-delayed renal-replacement strategy did not improve survival and trended toward harm compared with a delayed strategy.HR 1.6595% CI 1.09-2.50Read →
  • 2020STARRT-AKI Core⁠RRT timingIn 3,019 critically ill patients with acute kidney injury, accelerated renal-replacement therapy did not reduce mortality and increased dialysis dependence compared with a standard strategy.RR 1.0095% CI 0.93-1.09Read →
  • 2018PRESERVE⁠Contrast-associated AKIIn 5,177 high-risk patients undergoing angiography, intravenous sodium bicarbonate or acetylcysteine did not reduce contrast-associated kidney outcomes compared with control.Read →
  • 2017AMACING⁠Contrast-associated AKIIn 660 patients with CKD undergoing contrast procedures, withholding prophylactic intravenous hydration was non-inferior for preventing contrast-associated AKI compared with hydration.2.6% vs 2.7%Read →
  • 2017PrevAKI⁠Care bundlesIn 276 high-risk cardiac-surgery patients identified by biomarkers, a KDIGO care bundle reduced acute kidney injury compared with standard care.55.1% vs 71.7%Read →
  • 2016ELAIN⁠RRT timingIn 231 critically ill patients with acute kidney injury, early renal-replacement therapy reduced 90-day mortality compared with delayed initiation.HR 0.6695% CI 0.45-0.97Read →
  • 2016AKIKI⁠RRT timingIn 620 critically ill patients with stage 3 AKI, an early renal-replacement strategy did not improve survival compared with a delayed strategy.48.5% vs 49.7%Read →
  • 2009RENAL⁠RRT doseIn 1,508 critically ill patients with acute kidney injury, higher-intensity continuous renal-replacement therapy did not reduce mortality compared with lower-intensity therapy.OR 1.0095% CI 0.81-1.23Read →
  • 2008ATN⁠RRT doseIn 1,124 critically ill patients with acute kidney injury, intensive renal-replacement therapy did not reduce mortality compared with less-intensive therapy.OR 1.0995% CI 0.86-1.40Read →